DVS;IL1F;Interleukin;C9orf;IL-1F;IL33;C9orf26;DVS27;IL1F11;NF-HEV;NFEHEV;DVS27 related protein;IL-1F11;IL-33;Interleukin-1 family member 11;Interleukin-33;Nuclear factor from high endothelial venules;NFHEV;CHROMOSOME 9 OPEN READING FRAME 26;DKFZp586H0523;IL 1F11;IL 33;Interleukin 1 family member 11;Interleukin 33;INTERLEUKIN 33 NFHEV;Interleukin 33 precursor;Interleukin33;Interleukin-33 (109-270);NF HEV;Nuclear factor for high endothelial venules;OTTHUMP00000021041;RP11 575C20.2

E.coli

Ser112-Thr270

O95760

Human

18.1 kDa

18 kDa

None

Not validated for activity

> 95 % as determined by reducing SDS-PAGE.

< 0.01 EU per μg of the protein as determined by the LAL method.

Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

This product is provided as lyophilized powder which is shipped with ice packs.

Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Please refer to the printed manual for detailed information.

Interleukin-33 (IL-33) was initially discovered as a nuclear factor NF-HEV abundantly expressed in high endothelial venules. It is a 30-32 kD pro-inflammatory protein with intracellular and extracellular activities and a chromatin-associated cytokine of the IL-1 family with high sequence and structural similarity to IL-1 and IL-18. IL-33 is highly and selectively expressed by high endothelial venule endothelial cells (HEVECs) in human tonsils; Peyers&#39;s patches; and lymph nodes. It contains a bipartite nuclear localization signal at the C-terminus; and is targeted to the nucleus when ectopically expressed in human umbilical vein endothelial cells (HUVECs) and HeLa cells. The C-terminal fragment; corresponding to mature IL-33; binds and triggers signaling. IL-33 mediates its biological effects via Toll-interleukin 1 (IL-1) receptor (TIR) domain-containing receptor ST2; activates NF-kappaB and MAP kinases; and drives production of T(H)2-associated cytokines from in vitro polarized T(H)2 cells. In vivo; IL-33 induces the expression of IL-4; IL-5; and IL-13 and leads to severe pathological changes in mucosal organs. Human IL-33 is 270 amino acids in length.